Glp 1 outside metabolic disease
Glp 1 outside metabolic disease: 5 articles from Peptides Facts. Evidence-led reference on research peptides.
GLP-1 in Parkinson's: LixiPark Positive, Exenatide Null
A 156-person phase 2 found a 3.08-point difference on a motor scale at 12 months. A 194-person phase 3 of a related molecule found nothing at 96 weeks. Reconciling them is a design exercise, not a verdict on the class.
GLP-1 Agonists Outside Metabolic Disease: The Evidence
Liver, brain, heart, kidney and drinking behaviour have all been tested against GLP-1 receptor agonists in randomised trials. The results are not uniform, and the pattern they form is more informative than any single readout.
Semaglutide and Alcohol Use Disorder: A Phase 2 RCT
Forty-eight non-treatment-seeking adults, nine weeks, and a bar-laboratory endpoint. What the first randomised trial of a GLP-1 receptor agonist in alcohol use disorder measured, what moved, and what did not.
ESSENCE: Semaglutide and MASH Histology at 72 Weeks
Two biopsy-based co-primary endpoints were met in the first 800 participants. What each endpoint measures, why a one-stage fibrosis change is not reversal, and what the trial has not yet shown.
SURPASS-CVOT: Why Non-Inferiority Is Not Superiority
A hazard ratio of 0.92 with a confidence interval from 0.83 to 1.01 met one prespecified test and failed another. The trial is this site's worked example of how outcome trials are built and read.